אבוסינאגיס 50 מ"ג - Abbosynagis 50 mg
ש××× ×× !
×תר××¤× × ×¢××× ×:×××ר ×תר×פ×ת ×©× ××©×¨× ××ר×××ת.
×× ×תק××× ××××¢× ×¢× ×פסקת ש×××ק ×תר××¤× ×:×ער×ת ×××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת.
ת×ר×× ×¢×××× ××ר×× ×תר××¤× ×× ×××ק×תר×פ×ת ××× 14/05/19.
×תר××¤× × ×¢××× ×:×××ר ×תר×פ×ת ×©× ××©×¨× ××ר×××ת.
×× ×תק××× ××××¢× ×¢× ×פסקת ש×××ק ×תר××¤× ×:×ער×ת ×××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת.
ת×ר×× ×¢×××× ××ר×× ×תר××¤× ×× ×××ק×תר×פ×ת ××× 14/05/19.
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | J06BD Antiviral monoclonal antibodies | ||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | ת×× ×©×¨××¨× - I.M | ||||||||||||||||||
| צ×רת ××× ×× | ×××§× ×××× ×ª ת×××¡× ××ר×ק×, POWDER FOR SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | Synagis is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:- Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.- Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.- Children less than 2 years of age and with haemodynamically significant congenital heart disease. | ||||||||||||||||||
| |||||||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | ||||||||||||||||||
| ×ת××××ת × ×× | Contraindications | ||||||||||||||||||
| ת×פע×ת ××××× | Undesirable effects | ||||||||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | ||||||||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | ||||||||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | ||||||||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | ||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×××ס×× ×××ס 50 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ABBVIE S.R.L., ITALY |
| ×©× ××¢× ×ר×ש×× | ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 06/2000. ר×ש××× ×ת×ר××: 07/2010 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
השינוי האחרון נעשה בֹ־26 בפברואר 2025 ב־13:55